|
|
|
| Correlation between urine liver-type fatty acid binding protein, interleukin-18 levels and the degree of renal injury in patients with hepatitis B cirrhosis |
| XU Jiao1 ZHANG Ying1 WANG Yuanyuan1 ZHU Feng2▲ |
1. The Sixth Department of Hepatopathy, Dalian Public Health Clinical Center, Liaoning Province, Dalian 116031, China;
2. The Second Department of Nephrology, Xinhua Hospital Affiliated to Dalian University, Liaoning Province, Dalian 116021, China |
|
|
|
|
Abstract Objective To study the correlation between urine liver-type fatty acid binding protein (L-FABP), interleukin-18 (IL-18) levels and the degree of renal injury in patients with hepatitis B cirrhosis. Methods The clinical data of 90 patients with hepatitis B cirrhosis complicated with renal injury who were admitted to Dalian Public Health Clinical Center from February 2020 to June 2021 were retrospectively analyzed. According to the relevant staging criteria of acute kidney injury (AKI), 40 patients in AKI Ⅰ were included in the mild group, and 50 patients in AKI Ⅱ and Ⅲ were included in the severe group. Meanwhile, the clinical data of 40 patients with hepatitis B cirrhosis but without renal injury were selected as the control group. The levels of L-FABP and IL-18 in the urine of the three groups were detected and compared, and the relationship between the levels of L-FABP and IL-18 in the urine of patients with hepatitis B cirrhosis and the degree of renal injury was analyzed. Results The levels of urine L-FABP and IL-18 of patients in the severe group were higher than those in the control group and the mild group, the differences were statistically significant (P＜0.05). The levels of urine L-FABP and IL-18 of patients in the mild group were higher than those in the control group, the differences were statistically significant (P＜0.05). Spearman correlation analysis showed that the levels of urine L-FABP and IL-18 were positively correlated with the degree of renal injury in patients with hepatitis B liver cirrhosis (P＜0.05). Conclusion For patients with hepatitis B cirrhosis, the more severe the renal injury, the higher the levels of urine L-FABP and IL-18.
|
|
|
|
|
|
| [3] |
周一萌，王岩，路丽芳，等.肝硬化患者并发肾损害危险因素的回顾性分析[J].中国现代医学杂志，2019，29（20）：74-78.
|
| [4] |
常敏，孙芳芳，路遥，等.乙型肝炎病毒相关的慢加急性肝衰竭患者发生急性肾损伤的临床特点及预后研究[J].中华实验和临床病毒学杂志，2021，35（4）：378-383.
|
| [5] |
张巍，邵明亮，苗同国，等.慢性乙型肝炎病毒感染合并急性肾损伤的发病特点及近期预后分析[J].中国现代医学杂志，2020，30（1）：70-76.
|
| [1] |
曹敬，梁潇浪，张兰，等.影响乙型肝炎肝硬化失代偿期预后的相关因素分析[J].实用医院临床杂志，2020，17（1）：171-174.
|
| [2] |
刘潇，胡燕，孙艳君.血清ADM与尿TXB2对肝硬化失代偿期患者肾损伤的诊断效能研究[J].肝脏，2020，25（7）：709-713.
|
| [6] |
阎双缓.乙型肝炎肝硬化并发肾损害的危险因素及胱抑素C在诊断中的价值[J].河北医药，2019，41（23）：3595-3598.
|
| [7] |
张洁冰，郭宏华.乙型肝炎肝硬化合并肾损伤及抗病毒药物的应用[J].临床肝胆病杂志，2019，35（1）：191-196.
|
| [8] |
王晶晶，李竞，王勇强.老年脓毒症患者急性肾损伤的临床特征和预后[J].中华危重病急救医学，2019，31（7）：837-841.
|
| [9] |
中华医学会肝病学分会.肝硬化诊治指南[J].实用肝脏病杂志，2019，22（6）：770-786.
|
| [10] |
阎双缓，张红霞，何立芳，等.前列地尔治疗乙型肝炎肝硬化并发肾损伤疗效观察[J].现代中西医结合杂志，2019，28（9）：932-935.
|
| [11] |
刘艺琪，王芳芳，李萍.乙型肝炎肝硬化合并急性肾损伤的影响因素[J].中华传染病杂志，2018，36（12）：752-754.
|
| [12] |
王文娟，宋琦，丁惠国.肝硬化患者急性肾损伤的临床特点及危险因素分析[J].中华内科杂志，2018，57（12）：912-916.
|
| [13] |
康玮玮，段丽萍，徐曼曼，等.慢加急性肝衰竭与失代偿性肝硬化患者合并急性肾损伤的临床特点比较[J].中华肝脏病杂志，2020，28（5）391-396.
|
| [14] |
尹伟，李成忠，邹多武.肝功能基础对肝硬化及肝衰竭并发急性肾损伤转归及预后的影响[J].肝脏，2018，23（4）297-301.
|
| [15] |
欧进军，韩焕钦，郑伟强. 肝硬化并发急性肾损伤早期诊断生物标志物研究进展[J].肝脏，2018，23（3）：260-262.
|
| [16] |
潘俊娣，叶斌，戴木根，等.肝硬化合并急性肾损伤患者尿NGAL、L-FABP变化及意义[J].中西医结合肝病杂志，2019，29（1）：29-32.
|
| [17] |
康晓征，赵勇，乐磊，等.肝型脂肪酸结合蛋白对比白介素18对肝硬化失代偿期急性肾损伤患者的诊断价值[J].安徽医科大学学报，2018，53（8）：1289-1293.
|
| [18] |
孟淑荣，王山山.乙型肝炎肝硬化患者血清B7-H3和IL-18水平变化及其临床意义探讨[J].实用肝脏病杂志，2019，22（2）：224-227.
|
|
|
|
